Methyltransferase complex (MTC) deposits 6-adenosine (m A) onto RNA, whereas microprocessor produces miRNA. Whether and how these two distinct complexes cross-regulate each other has been poorly studied. Here we report that the MTC subunit B (MTB) tends to form insoluble condensates with poor activity, with its level monitored by 20S proteasome. Conversely, the microprocessor component SERRATE (SE) forms liquid-like condensates, which in turn promotes solubility and stability of MTB, leading to increased MTC activity. Consistently, the hypomorphic lines expressing SE variants, defective in MTC interaction or liquid-like phase behavior, exhibit reduced m A level. Reciprocally, MTC can recruit microprocessor to loci, prompting co-transcriptional cleavage of primary miRNA (pri-miRNAs) substrates. Additionally, pri-miRNAs carrying m A modifications at their single-stranded basal regions are enriched by m A readers, which retain microprocessor in the nucleoplasm for continuing processing. This reveals an unappreciated mechanism of phase separation in RNA modification and processing through MTC and microprocessor coordination.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11383662PMC
http://dx.doi.org/10.1101/2024.08.31.610644DOI Listing

Publication Analysis

Top Keywords

mtc
6
microprocessor
5
reciprocal regulation
4
regulation modification
4
modification mirna
4
mirna production
4
production machineries
4
machineries phase
4
phase separation-dependent
4
separation-dependent -independent
4

Similar Publications

Background: Multiple endocrine neoplasia type 2 syndrome (MEN2) is a hereditary disease resulting from mutations of the rearranged during transfection (RET) protooncogene subclassified into MEN2A [medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism] and MEN2B (MTC, pheochromocytoma, Marfanoid habitus, mucous neuromas, and intestinal ganglioneuromatosis). Prophylactic thyroidectomy is recommended in RET-mutated patients. The age at which it should be performed depends on the type and aggressiveness of the mutation.

View Article and Find Full Text PDF

Gross recurrent laryngeal nerve invasion by extranodal extension in thyroid carcinoma.

BMC Cancer

January 2025

Department of Ultrasound, Peking University Third Hospital, 49 North Garden Road, Haidian District, Beijing, 100191, China.

Background: Lymphatic metastasis commonly occurs in patients with papillary thyroid carcinoma and medullary thyroid carcinoma. The clinical and imaging characteristics of recurrent laryngeal nerve (RLN) invasion by extranodal extension (ENE) of metastatic lymph nodes remain understudied. This study aimed to evaluate these characteristics in patients with thyroid carcinoma.

View Article and Find Full Text PDF

Uncommon metastatic journey: unusual breast metastases of medullary thyroid carcinoma: a case report.

BMC Womens Health

January 2025

Department of Surgical Oncology, Salah Azaiez Institute, Faculty of Medicine of Tunis, University of Tunis El Manar, Boulevad 9 Avril Bab Saadoun 1006, Tunis, Tunisia.

Medullary thyroid carcinoma is a neuroendocrine tumor derived from thyroid C-cells. It is a rare aggressive tumor, known to metastasize to lymph nodes, liver, bones, and lungs. We report a case of a young patient with a family history of breast cancer, who developed breast metastases six months post-treatment for medullary thyroid carcinoma.

View Article and Find Full Text PDF

A 34-year-old male patient with recently diagnosed with medullary thyroid carcinoma underwent total thyroidectomy and radical neck dissection, requiring sharp dissection to separate the tumour from the trachea. He required post operative intubation due to bilateral vocal cord paralysis. He developed ischaemic necrosis of the upper two thirds of the trachea presenting with marked surgical emphysema and an infective wound.

View Article and Find Full Text PDF

Several exploratory studies have demonstrated the feasibility of cholecystokinin-2 receptor (CCK2R) targeting in patients with medullary thyroid carcinoma (MTC) and other neuroendocrine tumors (NETs). We report the results of a prospective phase I/IIA pilot study (clinicaltrials.gov NCT06155994) conducted at our center with the Ga-labeled peptide analog DOTA-DGlu-Ala-Tyr-Gly-Trp-(N-Me)Nle-Asp-1-Nal-Phe-NH (Ga-DOTA-MGS5).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!